BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36273457)

  • 1. Eribulin in Patients with Liposarcoma and Leiomyosarcoma: A Retrospective Single-Center Experience.
    Steinbrecher O; Brodowicz T; Raderer M; Scharrer A; Fabsits J; Lamm W
    Oncology; 2023; 101(2):89-95. PubMed ID: 36273457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy With Eribulin Following Potentially Curative Surgery in Patients With Localized Liposarcoma.
    Steinbrecher O; Brodowicz T; Popov P; Lamm W
    In Vivo; 2024; 38(1):385-389. PubMed ID: 38148100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
    Schöffski P; Chawla S; Maki RG; Italiano A; Gelderblom H; Choy E; Grignani G; Camargo V; Bauer S; Rha SY; Blay JY; Hohenberger P; D'Adamo D; Guo M; Chmielowski B; Le Cesne A; Demetri GD; Patel SR
    Lancet; 2016 Apr; 387(10028):1629-37. PubMed ID: 26874885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates.
    Haddox CL; Nathenson MJ; Mazzola E; Lin JR; Baginska J; Nau A; Weirather JL; Choy E; Marino-Enriquez A; Morgan JA; Cote GM; Merriam P; Wagner AJ; Sorger PK; Santagata S; George S
    Clin Cancer Res; 2024 Apr; 30(7):1281-1292. PubMed ID: 38236580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma.
    Nathenson MJ; Barysauskas CM; Nathenson RA; Regine WF; Hanna N; Sausville E
    World J Surg Oncol; 2018 Oct; 16(1):203. PubMed ID: 30309356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eribulin in advanced liposarcoma and leiomyosarcoma.
    Setola E; Noujaim J; Benson C; Chawla S; Palmerini E; Jones RL
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):717-723. PubMed ID: 28621163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
    Patel S; von Mehren M; Reed DR; Kaiser P; Charlson J; Ryan CW; Rushing D; Livingston M; Singh A; Seth R; Forscher C; D'Amato G; Chawla SP; McCarthy S; Wang G; Parekh T; Knoblauch R; Hensley ML; Maki RG; Demetri GD
    Cancer; 2019 Aug; 125(15):2610-2620. PubMed ID: 31173362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas.
    Noujaim J; Alam S; Thway K; Jones RL
    Indian J Med Paediatr Oncol; 2016; 37(3):125-30. PubMed ID: 27688604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
    De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
    Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.
    Demetri GD; Schöffski P; Grignani G; Blay JY; Maki RG; Van Tine BA; Alcindor T; Jones RL; D'Adamo DR; Guo M; Chawla S
    J Clin Oncol; 2017 Oct; 35(30):3433-3439. PubMed ID: 28854066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma.
    Kawai A; Araki N; Naito Y; Ozaki T; Sugiura H; Yazawa Y; Morioka H; Matsumine A; Saito K; Asami S; Isu K
    Jpn J Clin Oncol; 2017 Feb; 47(2):137-144. PubMed ID: 28173193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Biomarkers of Response to Eribulin in Patients with Leiomyosarcoma.
    Wozniak A; Boeckx B; Modave E; Weaver A; Lambrechts D; Littlefield BA; Schöffski P
    Clin Cancer Res; 2021 Jun; 27(11):3106-3115. PubMed ID: 33795257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen.
    Osgood CL; Chuk MK; Theoret MR; Huang L; He K; Her L; Keegan P; Pazdur R
    Clin Cancer Res; 2017 Nov; 23(21):6384-6389. PubMed ID: 28242632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma.
    Chen TW; Hsu CL; Hong RL; Lee JC; Chang K; Yu CW; Chen SC; Guo JC; Chen ML; Hsu MC; Kung TF; Cheng AL; Yen CC
    Clin Cancer Res; 2022 Dec; 28(23):5058-5065. PubMed ID: 36129471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma.
    Kim CG; Sim NS; Kim JE; Yun KH; Lee YH; Kim SH; Baek W; Han YD; Kim SK; Kim JH; Koh YW; Jung I; Shin SJ; Rha SY; Ahn JH; Kim HS
    Clin Cancer Res; 2022 Aug; 28(15):3225-3234. PubMed ID: 35583824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes.
    Kobayashi E; Naito Y; Asano N; Maejima A; Endo M; Takahashi S; Megumi Y; Kawai A
    Jpn J Clin Oncol; 2019 Oct; 49(10):938-946. PubMed ID: 31365116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SAR-096: Phase II Clinical Trial of Ribociclib in Combination with Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS).
    Movva S; Matloob S; Handorf EA; Choy E; Merriam P; Flieder DB; Cai KQ; Zhou Y; Tetzlaff ED; Pagan C; Barker E; Veggeberg R; Zumpano D; Rink L; von Mehren M; George S
    Clin Cancer Res; 2024 Jan; 30(2):315-322. PubMed ID: 37967116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
    Jones RL; Demetri GD; Schuetze SM; Milhem M; Elias A; Van Tine BA; Hamm J; McCarthy S; Wang G; Parekh T; Knoblauch R; Hensley ML; Maki RG; Patel S; von Mehren M
    Ann Oncol; 2018 Sep; 29(9):1995-2002. PubMed ID: 30084934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect?
    Escudero J; Heredia-Soto V; Wang Y; Ruiz P; Hu Y; Gallego A; Pozo-Kreilinger JJ; Martinez-Marin V; Berjon A; Ortiz-Cruz E; Bernabeu D; Feliu J; Tang J; Redondo A; Mendiola M
    Cancer Cell Int; 2021 Dec; 21(1):646. PubMed ID: 34863177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial.
    Wiemer EAC; Wozniak A; Burger H; Smid M; Floris G; Nzokirantevye A; Sciot R; Sleijfer S; Schöffski P
    Eur J Cancer; 2017 Apr; 75():33-40. PubMed ID: 28214655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.